Welcome to our dedicated page for DBV Technologies S.A. SEC filings (Ticker: DBVTF), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
DBV Technologies S.A.'s SEC filings document a foreign issuer reporting framework for ordinary shares and American Depositary Shares. Form 8-K reports furnish financial results and business highlights, disclose registered securities, and record material governance and compensation actions.
Proxy materials for DBV Technologies S.A. cover shareholder voting matters, board authorization, compensation committee recommendations and equity award authority under French corporate law. The filings also identify ADS terms in which each American Depositary Share represents five ordinary shares, with the ADSs registered on Nasdaq under DBVT.
DBV TECHNOLOGIES S.A. reported that Artisan Partners entities jointly beneficially own 2,219,386 American Depositary Shares, equal to 3.7% of the class. The filing states this stake is based on 59,208,489 shares outstanding as of 03/25/2026 and lists shared voting and dispositive powers.
The Schedule 13G/A is a joint filing by Artisan Partners Asset Management Inc., Artisan Partners Holdings LP, Artisan Investments GP LLC and Artisan Partners Limited Partnership and includes a joint filing agreement dated 05/13/2026.
DBV Technologies S.A. ownership disclosure: Vivo Opportunity entities report beneficial ownership positions in the issuer's Ordinary Shares represented by ADSs. Vivo Opportunity, LLC and its affiliated Delaware partnership report 11,820,005 Ordinary Shares (represented by 2,364,001 ADSs), equal to 4.0% of shares.
Related Cayman entities report 1,517,840 Ordinary Shares (represented by 303,568 ADSs), equal to 0.5%. The percent calculations use 296,042,447 Ordinary Shares outstanding as of April 30, 2026.
DBV Technologies S.A. adopted a new 2026 Performance Share Unit Plan and granted its CEO, Daniel Tassé, 1,740,000 Performance Share Units (PSUs) effective May 5, 2026. Each PSU is a conditional right to receive one ordinary share.
Half of the PSUs depend on each of two performance conditions tied to U.S. FDA acceptance for review or approval of biologics license applications for Viaskin Peanut, plus a continued employment requirement through July 1, 2028. Unmet PSUs by that date are forfeited. Vested shares are scheduled for delivery in four installments from July 1, 2028 through January 1, 2030, with change-in-control, death, disability, qualifying retirement and certain terminations receiving tailored treatment under the Plan, including potential cash settlement if the CEO is not a French tax resident.
DBV Technologies S.A. Schedule 13G/A amendment shows institutional holders led by Invus entities reporting beneficial ownership stakes in the issuer. Invus Public Equities beneficially held 17,997,870 ordinary shares as of March 31, 2026, representing 6.1% of the class. The filing states 296,042,447 shares outstanding as of March 25, 2026 (source: the issuer's Form 10-K).
The filing aggregates related parties and control links: Invus PE Advisors, Global Management, Siren, Avicenna entities, Ulys, and Raymond Debbane are disclosed as reporting persons or controlling entities; Mr. Debbane is the signing reporting person.
DBV Technologies reported first quarter 2026 results showing higher spending as it prepares for potential commercialization of its VIASKIN Peanut patch. Net loss widened to $47.6 million from $27.1 million a year earlier as research, sales, and administrative expenses increased sharply.
Research and development expenses rose to $33.4 million, while sales and marketing and general and administrative costs climbed to $4.8 million and $10.5 million, respectively. Despite the larger loss, basic and diluted net loss per share improved from $(0.26) to $(0.11) due to a strengthened equity base.
DBV ended March 31, 2026 with $229 million in cash and cash equivalents, up from $194 million at year-end 2025, supported by $89 million of financing cash flows from warrant exercises. Management currently expects this cash to fund operations into the second quarter of 2027.
DBV Technologies S.A. reported a larger net loss as it ramps up development and commercial preparation for its Viaskin Peanut patch. For the three months ended March 31, 2026, net loss widened to $47.6 million from $27.1 million a year earlier, driven by a sharp increase in operating expenses.
Research and development spending rose to $33.4 million, sales and marketing to $4.8 million, and general and administrative costs to $10.5 million, reflecting expanded clinical activity, pre-commercial inventory build, and build‑out of U.S. commercial and corporate infrastructure. There was still no product revenue; operating income of $0.9 million came mainly from the French research tax credit.
Following a 2025 PIPE financing and warrant exercises, DBV ended the quarter with $229.2 million in cash and cash equivalents, up from $194.2 million at year‑end 2025. Management estimates this cash should fund operations into the second quarter of 2027, assuming current plans focused on Viaskin Peanut, although faster spending or new programs could shorten that runway.
DBV Technologies S.A. files an amended annual report to add detailed Part III disclosures on governance, executive compensation, ownership and related-party transactions. The filing describes a 10‑member board with nine directors independent under Nasdaq rules and gender balance requirements under French law.
As of April 15, 2026, DBV had 296,042,447 ordinary shares outstanding and a public float valued at $250.9 million as of June 30, 2025. The company reports 2025 CEO compensation of $3.36 million, including salary, bonus and equity awards, and outlines its performance‑based pay philosophy and severance terms.
The document also details equity plans with 17.8 million awards outstanding and 17.7 million shares available, large April 2025 PIPE financing generating $125.5 million plus $195.2 million from January 2026 warrant exercises, and the holdings of major shareholders such as Baker Bros., Suvretta, MPM BioImpact and Janus.
DBV Technologies S.A. director Philina Lee filed an initial Form 3, which is a required statement of her beneficial ownership as an insider of the company. The filing shows no reportable transactions in the company’s securities at this time.
DBV Technologies reported full-year 2025 results showing continued investment ahead of a potential launch of its VIASKIN® Peanut Patch. Under U.S. GAAP, operating income was $5.6 million for the year ended December 31, 2025, up from $4.2 million in 2024, mainly from higher French research tax credits.
Research and development expenses rose to $116.7 million, while general and administrative expenses increased to $32.8 million, reflecting clinical progress and launch preparation. Net loss widened to $147.0 million versus $113.9 million in 2024, though net loss per share improved to $1.05 from $1.17. Including $94 million of warrant-related proceeds received in January 2026, management expects existing cash and cash equivalents to fund operations into the second quarter of 2027, based on current plans focused on the VIASKIN Peanut Patch.
DBV Technologies S.A. is a late-stage biopharmaceutical company developing Viaskin, an epicutaneous patch platform for food allergies, led by Viaskin Peanut. The patch delivers tiny doses of allergen through intact skin to Langerhans cells, aiming to desensitize patients while limiting systemic exposure.
Viaskin Peanut has shown positive Phase 3 results in toddlers (EPITOPE/EPOPEX) and children 4–7 years (VITESSE), with statistically significant increases in tolerated peanut dose and mainly local skin reactions. The company plans Biologics License Application submissions in the first and second half of 2026 for children 4–7 and 1–3 years old, including an FDA Accelerated Approval pathway for toddlers supported by the COMFORT Toddlers safety study.
DBV also pursues Viaskin Milk and earlier programs, but depends heavily on Viaskin Peanut. It reports a history of significant losses, potential future funding needs, extensive clinical and regulatory risk, manufacturing reliance on partners such as Sanofi and Fareva, intellectual property dependencies, and the risk of failing to maintain Nasdaq listing standards.